CR Double-Crane(SH:600062)2021-04-27 16:00Financial Performance - Operating revenue rose by 10.34% to CNY 2,407,751,720.57 year-on-year[7] - Net profit attributable to shareholders increased by 4.09% to CNY 286,211,847.38 compared to the same period last year[7] - The basic earnings per share rose by 4.09% to CNY 0.2743[7] - Net profit for Q1 2021 was CNY 297,164,529.40, up 7.63% from CNY 276,356,528.87 in Q1 2020[30] - Total operating revenue for Q1 2021 reached CNY 2,407,751,720.57, an increase of 10.34% compared to CNY 2,182,125,834.68 in Q1 2020[29] - The total profit for Q1 2021 was CNY 360,521,086.98, an increase from CNY 334,395,525.46 in Q1 2020[30] Assets and Liabilities - Total assets increased by 6.67% to CNY 13,245,136,617.11 compared to the end of the previous year[7] - As of March 31, 2021, total assets increased to CNY 13,245,136,617.11 from CNY 12,416,486,664.94 at the end of 2020, representing a growth of approximately 6.67%[24] - Current liabilities decreased to CNY 2,626,470,399.00 from CNY 2,670,030,590.72, a reduction of approximately 1.63%[25] - The total liabilities increased to CNY 3,126,769,667.61 from CNY 3,039,500,549.86, reflecting a growth of about 2.87%[25] - The total amount of entrusted financial management reached CNY 1,522,490,000.00, with actual earnings of CNY 4,888,169.34 during the reporting period[20] Cash Flow - Cash flow from operating activities decreased by 11.63% to CNY 322,732,752.17 compared to the previous year[7] - Cash received from tax refunds increased by ¥27,718,018.72, a surge of 2897.30%, mainly due to the consolidation of Tiandong Pharmaceutical[15] - Cash received from other operating activities rose by ¥13,707,999.11, an increase of 101.55%, driven by higher government subsidies and the consolidation of Tiandong Pharmaceutical[15] - Cash paid for purchasing goods and services increased by ¥223,284,339.85, a growth of 56.16%, primarily due to the consolidation of Tiandong Pharmaceutical[15] - The net cash flow from operating activities for Q1 2021 was approximately ¥322.73 million, down 11.6% from ¥365.21 million in Q1 2020[33] Investments and Expenses - R&D expenses increased by ¥29,180,120.94, a growth of 68.62%, mainly due to increased investment and the inclusion of Tiandong Pharmaceutical in the consolidation scope[14] - Interest expenses rose by ¥2,145,217.21, an increase of 325.81%, primarily due to the new leasing standards and retirement benefit plan interest expenses[14] - Investment income decreased by ¥681,109.38, a decline of 84.61%, attributed to reduced financial management income measured at amortized cost[14] - Research and development expenses increased to CNY 71,702,452.77 in Q1 2021, a rise of 68.83% from CNY 42,522,331.83 in Q1 2020[29] Equity and Shareholder Information - The total equity attributable to shareholders increased to CNY 9,564,035,770.79 from CNY 9,294,106,183.59, reflecting a growth of approximately 2.91%[25] - The company's total equity decreased slightly to approximately ¥9.36 billion as of January 1, 2021, from ¥9.38 billion at the end of 2020[39] - The company's retained earnings decreased by approximately ¥16.87 million, totaling ¥7.56 billion as of January 1, 2021[39] Consolidation and Changes - Minority interests increased by 568.84% to CNY 471,451,247.22, primarily due to the inclusion of Tiandong Pharmaceutical in the consolidation scope[13] - Cash from investment recovery increased by ¥322,536,184.74, a rise of 64.51%, mainly due to the recovery of matured financial products and the consolidation of Tiandong Pharmaceutical[15] - The company confirmed that there were no significant changes in net profit compared to the same period last year, ensuring stability in financial performance[21] - The company has undergone legal procedures for all financial management activities, ensuring compliance and transparency[20]